Therapeutic Approaches to Gastric Hepatoid Adenocarcinoma: Current Perspectives

References

• Bourreille J, Metayer P, Sauger F, Fondimare A. Existence d`alpha fetoprotein au cours d`un cancer secondaire du foie d`origine gastrique. Press Med. 1970;78(28):1277–1278.5426134
   PubMed Web of Science ®Google Scholar
• Ishikura H, Fukasawa Y, Ogasawara K, Natori T, Tsukada Y, Aizawa M. An AFP-producing gastric carcinoma with features of hepatic differentiation. A case report. Cancer. 1985;56(4):840–848. doi:10.1002/(ISSN)1097-01422410093
   PubMed Web of Science ®Google Scholar
• Zeng XY, Yin YP, Xiao H, et al. Clinicopathological characteristics and prognosis of hepatoid adenocarcinoma of the stomach: evaluation of a pooled case series. Curr Med Sci. 2018;38(6):1054–1061. doi:10.1007/s11596-018-1983-130536069
   PubMed Web of Science ®Google Scholar
• Zeng X, Zhang P, Xiao H, et al. Clinicopathological features and prognosis of intestinal hepatoid adenocarcinoma: evaluation of a pooled case series. Oncotarget. 2018;9(2):2715–2725. doi:10.18632/oncotarget.v9i229416804
   PubMedGoogle Scholar
• Yang J, Wang R, Zhang W, Zhuang W, Wang M, Tang C. Clinicopathological and prognostic characteristics of hepatoid adenocarcinoma of the stomach. Gastroenterol Res Pract. 2014;2014:140587. doi:10.1155/2014/14058724669215
   PubMed Web of Science ®Google Scholar
• Hu M, Liu W, Yin F, Zhang D, Liu X, Lai J. Liver metastasis of hepatoid colonic adenocarcinoma: a rare and unusual entity with poor prognosis and review of the literature. Gastroenterol Res. 2018;11(6):430–435. doi:10.14740/gr1097
   PubMed Web of Science ®Google Scholar
• Søreide JA, Greve OJ, Gudlaugsson E, Størset S. Hepatoid adenocarcinoma of the stomach–proper identification and treatment remain a challenge. Scand J Gastroenterol. 2016;51(6):646–653. doi:10.3109/00365521.2015.112428626728165
   PubMed Web of Science ®Google Scholar
• Grossman K, Beasley MB, Braman SS. Hepatoid adenocarcinoma of the lung: review of a rare form of lung cancer. Respir Med. 2016;119:175–179. doi:10.1016/j.rmed.2016.09.00327692141
   PubMed Web of Science ®Google Scholar
• Devi NR, Sathyalakshmi R, Devi J, Lilly SM. Hepatoid adenocarcinoma of the gall bladder-a rare variant. J Clin Diagn Res. 2015;9(8):ED09–ED10. doi:10.7860/JCDR/2015/10799.6324
   PubMedGoogle Scholar
• Marchegiani G, Gareer H, Parisi A, Capelli P, Bassi C, Salvia R. Pancreatic hepatoid carcinoma: a review of the literature. Dig Surg. 2013;30(4–6):425–433. doi:10.1159/00035544224281319
   PubMed Web of Science ®Google Scholar
• Kuroda N, Onishi K, Lee GH. Combined tubular adenocarcinoma and hepatoid adenocarcinoma arising in barrett esophagus. Ann Diagn Pathol. 2011;15(6):450–453. doi:10.1016/j.anndiagpath.2010.06.00620952273
   PubMed Web of Science ®Google Scholar
• Fakhruddin N, Bahmad HF, Aridi T, et al. Hepatoid adenocarcinoma of the stomach: a challenging diagnostic and therapeutic disease through a case report and review of the literature. Front Med. 2017;4:164. doi:10.3389/fmed.2017.00164
   Web of Science ®Google Scholar
• Xie Y, Zhao Z, Li P, et al. Hepatoid adenocarcinoma of the stomach is a special and easily misdiagnosed or missed diagnosed subtype of gastric cancer with poor prognosis but curative for patients of pN0/1: the experience of a single center. Int J Clin Exp Med. 2015;8(5):6762–6772.26221214
   PubMed Web of Science ®Google Scholar
• Adachi Y, Tsuchihashi J, Shiraishi N, Yasuda K, Etoh T, Kitano S. AFP-producing gastric carcinoma: multivariate analysis of prognostic factors in 270 patients. Oncology. 2003;65(2):95–101. doi:10.1159/00007233212931013
   PubMed Web of Science ®Google Scholar
• Zhang J, Shi S, Shao Y, Zhang H. Clinicopathological and prognostic features of hepatoid adenocrcinoma of the stomach. Chin Med J. 2011;124(10):1470–1476.21740800
   PubMed Web of Science ®Google Scholar
• Qu BG, Bi WM, Qu BT, et al. PRISMA-compliant article: clinical characteristics and factors influencing prognosis of patients with hepatoid adenocarcinoma of the stomach in China. Medicine (Baltimore). 2016;95(15):e3399. doi:10.1097/MD.000000000000339927082614
   PubMed Web of Science ®Google Scholar
• Liu X, Sheng W, Wang Y. An analysis of clinicopathological features and prognosis by comparing hepatoid adenocarcinoma of the stomach with AFP-producing gastric cancer. J Surg Oncol. 2012;106(3):299–303. doi:10.1002/jso.v106.322389029
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Matsuzaki I, Nishino M, et al. HER2 is frequently overexpressed in hepatoid adenocarcinoma and gastric carcinoma with enteroblastic differentiation: a comparison of 35 cases to 334 gastric carcinomas of other histological types. J Clin Pathol. 2018;71(7):600–607. doi:10.1136/jclinpath-2017-20492829305518
   PubMed Web of Science ®Google Scholar
• Ishikura H, Kirimoto K, Shamoto M, et al. Hepatoid adenocarcinomas of the stomach. An analysis of seven cases. Cancer. 1986;58(1):119–126. doi:10.1002/1097-0142(19860701)58:1<119::AID-CNCR2820580121>3.0.CO;2-U2423220
   PubMed Web of Science ®Google Scholar
• Inoue M, Sano T, Kuchiba A, Taniguchi H, Fukagawa T, Katai H. Long-term results of gastrectomy for alpha-fetoprotein-producing gastric cancer. Br J Surg. 2010;97(7):1056–1061. doi:10.1002/bjs.708120632272
   PubMed Web of Science ®Google Scholar
• Liu X, Cheng Y, Sheng W, et al. Analysis of clinicopathologic features and prognostic factors in hepatoid adenocarcinoma of the stomach. Am J Surg Pathol. 2010;34(10):1465–1471. doi:10.1097/PAS.0b013e3181f0a87320871221
   PubMed Web of Science ®Google Scholar
• Lin CY, Yeh HC, Hsu CM, Lin WR, Chiu CT. Clinicopathologial features of gastric hepatoid adenocarcinoma. Biomed J. 2015;38(1):65–69. doi:10.4103/2319-4170.12686025163499
   PubMed Web of Science ®Google Scholar
• Su JS, Chen YT, Wang RC, Wu CY, Lee SW, Lee TY. Clinicopathological characteristics in the differential diagnosis of hepatoid adenocarcinoma: a literature review. World J Gastroenterol. 2013;19(3):321–327. doi:10.3748/wjg.v19.i3.32123372352
   PubMed Web of Science ®Google Scholar
• Chang YC, Nagasue N, Kohno H, et al. Clinicopathologic features and long-term results of alpha-fetoprotein-producing gastric cancer. Am J Gastroenterol. 1990;85(11):1480–1485.1700600
   PubMed Web of Science ®Google Scholar
• Shen Z, Liu X, Lu B, Ye M. Hepatoid adenocarcinoma of the stomach: a case report of a rare type of gastric cancer. Oncol Lett. 2016;11(2):1077–1080. doi:10.3892/ol.2015.402326893695
   PubMed Web of Science ®Google Scholar
• Xiao C, Wu F, Jiang H, et al. Hepatoid adenocarcinoma of the stomach: nine case reports and treatment outcomes. Oncol Lett. 2015;10(3):1605–1609. doi:10.3892/ol.2015.343026622718
   PubMed Web of Science ®Google Scholar
• Chang MY, Kim HJ, Park SH, et al. CT features of hepatic metastases from hepatoid adenocarcinoma. Abdom Radiol (NY). 2017;42(10):2402–2409. doi:10.1007/s00261-017-1150-328421242
   PubMed Web of Science ®Google Scholar
• Lin YY, Chen CM, Huang YH, et al. Liver metastasis from hepatoid adenocarcinoma of the stomach mimicking hepatocellular carcinoma: dynamic computed tomography findings. World J Gastroenterol. 2015;21(48):13524–13531. doi:10.3748/wjg.v21.i48.1352426730164
   PubMed Web of Science ®Google Scholar
• Velut G, Mary F, Aflalo V, Aparicio T. Magnetic resonance imaging diffusion-weighted imaging for diagnosis of a gastric hepatoid adenocarcinoma. Dig Liver Dis. 2015;47(2):174. doi:10.1016/j.dld.2014.08.04425249152
   PubMedGoogle Scholar
• Seo HJ, Chung JK, Go H, Cheon GJ, Lee DS. A hepatoid adenocarcinoma of the stomach evaluated with (18)F-FDG PET/CT: intense (18)F-FDG uptake contrary to the previous report. Clin Nucl Med. 2014;39(5):442–445. doi:10.1097/RLU.000000000000027524152637
   PubMed Web of Science ®Google Scholar
• Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: classification, histology and application of molecular pathology. J Gastrointest Oncol. 2012;3(3):251–261. doi:10.3978/j.issn.2078-6891.2012.02122943016
   PubMedGoogle Scholar
• Wang Y, Sun L, Li Z, et al. Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features. Gastric Cancer. 2019;22(6):1–10. doi:10.1007/s10120-019-00965-530167905
   PubMed Web of Science ®Google Scholar
• Nagai E, Ueyama T, Yao T, Tsuneyoshi M. Hepatoid adenocarcinoma of the stomach. A clinicopathologic and immunohistochemical analysis. Cancer. 1993;72(6):1827–1835. doi:10.1002/(ISSN)1097-01427689918
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697. doi:10.1016/S0140-6736(10)61121-X20728210
   PubMed Web of Science ®Google Scholar
• Osada M, Aishima S, Hirahashi M, et al. Combination of hepatocellular markers is useful for prognostication in gastric hepatoid adenocarcinoma. Hum Pathol. 2014;45(6):1243–1250. doi:10.1016/j.humpath.2014.02.00324767858
   PubMed Web of Science ®Google Scholar
• Coburn N, Cosby R, Klein L, et al. Staging and surgical approaches in gastric cancer: a systematic review. Cancer Treat Rev. 2018;63:104–115. doi:10.1016/j.ctrv.2017.12.00629275224
   PubMed Web of Science ®Google Scholar
• Schwarz RE. Current status of management of malignant disease: current management of gastric cancer. J Gastrointest Surg. 2015;19(4):782–788. doi:10.1007/s11605-014-2707-x25591828
   PubMed Web of Science ®Google Scholar
• Simmet V, Noblecourt M, Lizee T, et al. Chemotherapy of metastatic hepatoid adenocarcinoma: literature review and two case reports with cisplatin etoposide. Oncol Lett. 2018;15(1):48–54. doi:10.3892/ol.2017.726329387209
   PubMed Web of Science ®Google Scholar
• Yuan DD, Zhu ZX, Zhang X, Liu J. Targeted therapy for gastric cancer: current status and future directions (review). Oncol Rep. 2016;35(3):1245–1254. doi:10.3892/or.2015.452826718131
   PubMed Web of Science ®Google Scholar
• Arakawa Y, Tamura M, Aiba K, et al. Significant response to ramucirumab monotherapy in chemotherapy-resistant recurrent alpha-fetoprotein-producing gastric cancer: a case report. Oncol Lett. 2017;14(3):3039–3042. doi:10.3892/ol.2017.651428928842
   PubMed Web of Science ®Google Scholar
• Wang FQ, Lu Q, Yan J, et al. Ex vivo hepatectomy and partial liver autotransplantation for hepatoid adenocarcinoma: a case report. Oncol Lett. 2015;9(5):2199–2204. doi:10.3892/ol.2015.304126137040
   PubMed Web of Science ®Google Scholar
• Okita K, Noda K, Kodama T, et al. Carcino-fetal proteins and gastric cancer: the site of alpha-fetoprotein synthesis in gastric cancer. Gastroenterol Jpn. 1977;12(5):400–406. doi:10.1007/BF0277453874349
   PubMedGoogle Scholar
• Zhang S. Cerebral metastaseis from hepatoid adenocarcinoma of the stomach. World J Gastroenterol. 2007;13(43):5787–5793. doi:10.3748/wjg.v13.i43.578717963312
   PubMed Web of Science ®Google Scholar
• Bi WL, Hosny A, Schabath MB, et al. Artificial intelligence in cancer imaging: clinical challenges and applications. CA Cancer J Clin. 2019;69(2):127–157. doi:10.3322/caac.2155230720861
   PubMed Web of Science ®Google Scholar
• Siravegna G, Mussolin B, Venesio T, et al. How liquid biopsies can change clinical practice in oncology. Ann Oncol. 2019;30(10):1580–1590. doi:10.1093/annonc/mdz22731373349
   PubMed Web of Science ®Google Scholar
• Dong D, Tang L, Li ZY, et al. Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer. Ann Oncol. 2019;30(3):431–438. doi:10.1093/annonc/mdz00130689702
   PubMed Web of Science ®Google Scholar